After receiving permission to build a £350 million biomanufacturing facility at a former GSK site in Ulverston, UK last year, Lakes BioSciences’ plan has reportedly fallen through. In February 2021, contact development manufacturing organization (CDMO) Lakes BioScience was granted permission from South Lakeland District to build a facility on GlaxoSmithKline’s (GSK) site located on North Lonsdale Road, Ulverston, Cumbria. Lakes BioScience director, Pat McIver told BioProcess Insider at the time that £350 million ($490 million) was being invested to build a monoclonal…

Lonza has expanded its Cocoon platform functionality by adding capabilities in cell separation, cell binding, and bead removal. The Cocoon platform is a single system that can be used for a wide-range of different autologous cell therapy protocols, with each patient batch produced in a single disposable cassette customized to their specific process. The platform was developed by Octane Biotech with help from Swiss contract development manufacturing organization (CDMO) Lonza, which has worked with the firm since 2015. In October…

ThermoGenesis has leased a facility in Sacramento, California to house its newly launched CDMO cell therapy business TG Biosynthesis.  ThermoGenesis (formerly known as Cesca Therapeutics), which provides cell processing tools and services to the cell and gene therapy sector, is bolstering its offering by creating a cell therapy production division.   The firm will deliver contract development manufacturing organization (CDMO) services under the name TG Biosynthesis. To create this, ThermoGenesis entered into a license and technology agreement with Boyalife Genomics, a…

Abzena has secured $65 million in additional funding to expand its production facilities to meet the increased demand in the industry. Contract development manufacturing organization (CDMO) Abzena says the latest investment from Welsh, Carson, Anderson & Stowe, and Biospring Partners will allow the firm to meet growing demand by increasing the capacity of its manufacturing capabilities for clinical and commercial supply. “At Abzena, we put patients at the center of all that we do. This new capital will allow us…

The CDMO has expanded its facilities by a further 22,600 square feet to relieve its capacity constraints. Contract development and manufacturing organization (CDMO) Exothera was founded in March 2020 by Belgium-based bioprocess tech firm Univercells, to offer cell and gene therapy developers process development and viral vector manufacturing. After expanding its two facilities in Jumet, Belgium about 25 km south of Brussels, and selecting bioprocess vendor Pall Corporation to equip the roughly 92,000 square feet of space in July 2021,…

eTheRNA Manufacturing introduces a lipid nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical advancement of RNA-based therapeutics and vaccines. According to the RNA technology firm, the LNP service uses eTheRNA’s lipid libraries and formulations to enable targeted delivery and tailored biodistribution solutions. Additionally, the service has been developed to allow customers to maximize the delivery of their RNA-products. “This service can cover product needs for early research and development and can be further optimized…

ten23 health will add 1000 square meters at its site in Visp, Switzerland by expanding into an adjacent building. The contract development manufacturing organization (CDMO) acquired its Visp, canton of Valais, Switzerland manufacturing site from swissfillon last October. Now, the firm will add 1,000 square meters of clean room space to enlarge its cold storage and visual inspection capacity. “ten23 health needs to increase the supporting infrastructure in order to utilize our assets for sterile production in Visp,” a spokesperson…

Wockhardt and Serum Life Sciences UK have partnered to build a facility in Wrexham, Wales to manufacture various vaccines. Wockhardt, headquartered in Mumbai, India said the collaboration with Serum Life Sciences UK (a subsidiary of the Serum Institute of India) will deliver an additional 150 million doses of a wide range of vaccines through building a fill-finish facility in Wrexham, North Wales. “We are delighted to have formed a strategic partnership between Wockhardt and Serum Life Sciences. The collaboration will…